Early-stage biosensor Invitrometrix offers a multi-well whole-cell QCM biosensor enabling real-time, label-free measurements of cellular biomechanics across various cell types, presenting a compelling entry point for biotech and pharma customers seeking phenotypic readouts in drug discovery programs.

Collaborative services Beyond hardware, Invitrometrix provides collaborative research and drug discovery services covering target identification, validation, safety and efficacy in multiple organ systems, and mechanism of action insights, creating a turnkey value proposition for potential partnerships and outsourcing.

Disease modeling The platform supports monitoring differentiation and disease onset (including neuron differentiation and degeneration) and can study multi-subunit receptor signaling, offering opportunities to engage with companies focusing on neurodegenerative, cardiovascular, and membrane receptor biology.

Orphan drug potential The QCM’s ability to study repurposing of orphan molecules and ligands with multi-receptor interactions positions Invitrometrix as a partner for niche programs seeking fast, real-time phenotypic feedback and mechanism insights.

SMB agility With a lean company profile and revenue under one million, Invitrometrix can be an attractive collaborator for CROs and biotech startups seeking flexible engagements, pilot studies, and co-development ventures without the overhead of large incumbents.